1

Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 1 and BRCA2 Variant Curation Expert Panel 2

3

Authors and Affiliations: 4

- Michael T. Parsons¹, Miguel de la Hoya², Marcy E. Richardson³, Emma Tudini¹, Michael Anderson⁴, Windy Berkofsky-Fessler⁵, 5
- 6 Sandrine M. Caputo⁶, Raymond C. Chan⁷, Melissa C. Cline⁸, Bing-Jian Feng⁹, Cristina Fortuno¹, Encarna Gomez-Garcia¹⁰,
- Johanna Hadler¹, Susan Hiraki⁵, Megan Holdren¹¹, Claude Houdaver¹², Kathleen Hruska⁵, Paul James¹³, Rachid Karam³, Huei San 7
- Leong¹⁴, Alexandra Martins¹⁵, Arjen R. Mensenkamp¹⁶, Alvaro N. Monteiro¹⁷, Vaishnavi Nathan¹, Robert O'Connor⁷, Inge Sokilde 8
- Pedersen¹⁸⁻²⁰, Tina Pesaran³, Paolo Radice²¹, Gunnar Schmidt²², Melissa Southey²³⁻²⁵, Sean Tavtigian²⁶, Bryony A. Thompson²⁷, 9
- Amanda E. Toland²⁸, Clare Turnbull²⁹, Maartje J. Vogel³⁰, Jamie Weyandt³, George A.R. Wiggins³¹, Lauren Zec³², Fergus J. 10
- Couch¹¹, Logan C. Walker³¹, Maaike P. G. Vreeswijk³³, David E. Goldgar⁹, Amanda B. Spurdle^{1, 34} 11
- 12 ¹ Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
- ² Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain. 13
- 14 ³ Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.
- ⁴ Invitae Corporation, San Francisco, CA, USA. 15
- ⁵ GeneDx, Gaithersburg, Maryland, USA. 16
- ⁶ Department of Genetics, Institut Curie, 75005 Paris, France and Paris Sciences Lettres Research University, Paris, 75005, 17 France.
- 18
- ⁷ Color Health, Burlingame, CA, USA. 19
- ⁸ UC Santa Cruz Genomics Institute, Mail Stop: Genomics, University of California, 1156 High Street, Santa Cruz, CA, 95064. 20 21 USA.
- 22 ⁹ Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA,
- ¹⁰ Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands. 23
- ¹¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 24
- 25 ¹² Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics, FHU G4 génomique F-76000 Rouen, France.
- 26 ¹³ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
- ¹⁴ Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia. 27
- ¹⁵ Univ Rouen Normandie, Inserm U1245, F-76000 Rouen, France, 28
- ¹⁶ Department of Human Genetics, Radboud university medical center, Nijmegen, the Netherlands. 29
- 30 ¹⁷ Department of Cancer Epidemiology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
- 31 ¹⁸ Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark.
- ¹⁹ Dept. of Clinical Medicine, Aalborg University, Denmark. 32
- ²⁰ Clinical Cancer Research Center, Aalborg University Hospital, Denmark. 33
- ²¹ Predictive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto 34 Nazionale dei Tumori, Via Venezian 1, 20133, Milano, Italy. 35
- ²² Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany. 36
- ²³ Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VC, Australia. 37
- ²⁴ Precision Medicine, School of Clinial Sciencs at Monash Health, Monash University, Clayton, Victoria, 3168, Australia. 38
- ²⁵ Department of Clinical Pathology, The Melbourne Medicial School, The University of Melbourne, Victoria, 3010, Australia. 39
- ²⁶ Department of Oncological Sciences and Huntsman Cancer Institute. University of Utah. Salt Lake City. UT 84132, USA. 40
- ²⁷ Department of Pathology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia. 41
- ²⁸ Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210, USA. 42
- ²⁹ Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. 43
- 44 ³⁰ Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
- ³¹ Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand. 45
- ³² Natera, Inc. San Carlos, CA, USA, 46
- ³³ Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands. 47
- ³⁴ Faculty of Medicine, University of Queensland, Australia. 48
- 49

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

52 Abstract

53

- The ENIGMA research consortium (https://enigmaconsortium.org/) develops and applies methods to determine clinical significance of variants in Hereditary Breast and Ovarian Cancer genes. An ENIGMA *BRCA1/2* classification sub-group, originally formed in 2016 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Federal Drug Administration recognized processes for ClinVar contributions.
- The VCEP reviewed American College of Medical Genetics/Association of Molecular Pathology (ACMG/AMP) classification criteria for relevance to interpreting *BRCA1* and *BRCA2* variants. Statistical methods were used to calibrate evidence strength for different
- 60 data types. Pilot specifications were tested on 40 variants, and documentation revised for clarity and ease-of-use.

The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 Uncertain Significance or Conflicting, 14 Pathogenic and/or Likely Pathogenic, and 13 Benign and/or Likely Benign. Review resolved classification for 11/13 Uncertain Significance or Conflicting variants, and retained or improved confidence in classification for the remaining variants.

Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several gaps in both the research processes and the baseline ACMG/AMP criteria. Calibration of evidence types was key to justify utility and strength of different evidence types for gene-specific application. The gene-specific criteria demonstrated value for improving ACMG/AMP-aligned classification of *BRCA1* and *BRCA2* variants.

71

72 Keywords

73 BRCA1; BRCA2; ClinGen; VCEP; ACMG/AMP variant curation guidelines; ClinVar

3

76 Introduction

The role of BRCA1 (MIM 113705) and BRCA2 (MIM 600185) in Hereditary Breast and Ovarian Cancer (HBOC) has long been 77 recognized, with genetic testing initiated soon after discovery of these genes in the 1990s.^{1; 2} The ENIGMA international research 78 consortium (https://enigmaconsortium.org/)³ focuses on development and application of methods to determine the clinical 79 80 significance of sequence variants in HBOC genes. The consortium has members from six continents that provide a broad range of expertise, under the umbrellas of analytical, splicing, functional, pathology and clinical working groups, for translational research 81 82 projects. At the request of ClinGen, in 2016 ENIGMA formed an external expert panel for curation of BRCA1 and BRCA2 variants. The classification criteria documented for this purpose (no longer used, Supplemental Information, Section 1) captured qualitative 83 criteria generally adopted clinically (e.g., most premature termination codon variants were assumed to be pathogenic), and 84 guantitative multifactorial likelihood analysis methods developed in the research setting.⁴⁻⁸ The key component of the multifactorial 85 86 likelihood approach is the statistical calibration of independent data types using variants of known pathogenicity status, to inform the weight of evidence towards or against pathogenicity. The external expert panel guidelines were then used to assign 7.456 expert 87 curations for BRCA1 and BRCA2 variants in ClinVar. 88

In parallel to these efforts, there was increasing international uptake of variant classification guidelines published by the American 89 College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP)⁹ for diagnostic interpretation of 90 germline sequence variants, with applicability to any Mendelian disease gene. In 2020, the ENIGMA external expert panel sought to 91 become an internal ClinGen Variant Curation Expert Panel (VCEP),^{10; 11} to align with Federal Drug Agency (FDA) recognized 92 93 processes for expert panel contributions to ClinVar. Here, we provide an overview of the evidence-based approach taken to consider 94 relevance of each ACMG/AMP evidence code for curation of variants in BRCA1 and BRCA2, and report pilot study results demonstrating the value of detailed (gene-specific) specifications to assist variant curation and resolve discordances and uncertainty 95 in variant classification. 96

97 Methods

98 The establishment and activities of the ClinGen BRCA1 and BRCA2 VCEP followed the ClinGen FDA-recognised approval process

99 (https://clinicalgenome.org/docs/guidelines-for-applying-for-variant-or-gene-curation-expert-panel-status/), with reference to

100 Protocol Version 8 at the time of VCEP initiation.

101 The original ENIGMA *BRCA1* and *BRCA2* expert panel membership, which was largely comprised of representatives from major 102 national clinical and research initiatives in Australia, Europe and USA, was expanded to include representatives from several major

4

diagnostic testing laboratories from the United States with extensive experience in the application of ACMG/AMP guidelines. The
 resulting ClinGen ENIGMA *BRCA1* and *BRCA2* VCEP consists of research and clinical experts from around the world, including
 Australasia, Europe and the United States. VCEP members met approximately monthly to review the baseline ACMG/AMP sequence
 variant classification guidelines⁹ to determine whether each classification criterion should be adopted, modified, or omitted for *BRCA1* and *BRCA2* variant interpretation.

Both *BRCA1* and *BRCA2* were designated as genes for which loss of function is a known mechanism of disease. Reference sequences used for annotation are as follows:

110 BRCA1. Coding DNA reference sequence from genomic RefSeq NG_005905.2 (same as LRG 292, Ensembl ENSG00000012048)

111 covering BRCA1 transcript NM_007294.4 (Ensembl transcript ENST00000357654.9). Exons are sequentially numbered to match

the exon descriptions of the MANE Select transcript (NM_007294.4). Exon numbering of BRCA1 has historically been according to

GenBank U14680.1, with exon 4 missing due to a correction made after the initial description of the gene, termed here as legacyexon numbering.

BRCA2. Coding DNA reference sequence from genomic RefSeq NG_012772.3 (same as LRG 293, Ensembl ENSG00000139618),
 covering BRCA2 transcript NM_000059.4 (MANE Select transcript; Ensembl transcript ENST00000380152.8).

117

The classification tiers in pre-existing ENIGMA external panel classification criteria for BRCA1 and BRCA2 (Supplemental 118 Information, Section 1) grouped multiple sources of information (e.g. frequency data, variant type, tumor pathology, co-occurrence 119 with a pathogenic variant, etc). A critical aspect of VCEP activities was to convert these grouped criteria to align with ACMG/AMP 120 codes representing different classification criteria, falling under the broad evidence types described for the ACMG/AMP framework 121 (i.e. population, computation/predictive, functional, segregation, de novo, allelic, other).9 Statistical methods were used to calibrate 122 strength of evidence (i.e. supporting, moderate, strong, very strong and stand-alone) for different data types following approaches 123 as outlined previously; and likelihood ratio (LR) estimates towards or against pathogenicity were derived for a given evidence type ¹² 124 and used to assign weights for or against pathogenicity following recommendations arising from Bayesian modelling of the 125 ACMG/AMP guidelines.¹³ Alongside, key members of the ClinGen Seguence Variant Interpretation Working Group (SVI WG) 126 (https://clinicalgenome.org/working-groups/sequence-variant-interpretation/) were consulted about how to capture valuable 127 information sources and analytical approaches that were used previously for external expert panel classification, but that did not 128 strictly conform to ACMG/AMP evidence types and designated codes/strengths. Extensive documentation supporting the rationale 129 for application and weighting of each code was compiled for ClinGen SVI WG review, following the standard VCEP approval protocol. 130

5

Specifications for codes relating to the use of computational and experimental evidence relevant to variant impact on RNA splicing 131 were informed by parallel development of recommendations from the ClinGen SVI Splicing Subgroup.¹⁴ After addressing feedback 132 from the SVI WG, the draft documentation was provided to nine VCEP members who had self-nominated to act as biocurators. As 133 biocurators they review and evaluate evidence relevant for variant classification, assign relevant ACMG/AMP codes and weights for 134 the available evidence, and ascribe a final pathogenicity classification based on the information reviewed. The draft specifications 135 were tested on 40 pilot variants, selected to capture variants spanning different assumed molecular impact, and different pre-existing 136 classifications in ClinVar (Supplemental Information, Section 2, Table S1), VCEP members were requested to provide any internal 137 data of relevance for classification of these 40 variants. Initial ClinVar summary classification descriptions were as follows: Pathogenic 138 (P), n=11; Likely Pathogenic/Pathogenic (LP/P), n=3; Uncertain Significance (VUS), n=4; Benign/Likely Benign (B/LB), n=1; Benign 139 (B), n=12; Conflicting, n=9. Conflicting Classifications represented various combinations of individual submitter classifications (details 140 provided in Table S1). 141

142 To facilitate the curation process, each biocurator was provided a file with the following variant-specific information: population frequency as reported in anomAD (v2.1 exomes only and v3.1); existing multifactorial LR data (spanning segregation, family history, 143 tumour pathology, case-control and co-occurrence LRs); protein functional assay data; mRNA splicing assay data; bioinformatic 144 impact predictions (missense, in-frame, splicing); clinical features of Fanconi Anemia (FA) cases as drawn from the literature and 145 additional internal laboratory data relevant for classification as provided by VCEP members. The latter included splicing assay results, 146 co-segregation data, presence or absence of FA phenotype for individuals with co-occurring variants. Protein functional assay data 147 was provided with functional category (impact, no impact or partial/indeterminate) assigned for all functional assays considered 148 relevant, with a summary description of the combined results. RNA assay data required evaluation by individual biocurators to assign 149 code weights. Each variant was curated by the lead biocurator (MTP) and two additional biocurators. The lead biocurator reviewed 150 curations for consistency in code application (including code strength), and final variant classification. Collated findings were 151 discussed with all VCEP members to identify factors contributing to between-biocurator differences in use of the specifications. 152

After this initial phase of variant review, biocurator feedback was used to inform revision of the documentation for clarity and ease of use. This included development of simplified look-up tables. At this time codes relating to bioinformatic predictions were updated to allow three categories: evidence towards pathogenicity, against pathogenicity and no bioinformatic code applicable. These updates were based on results from published splicing prediction analyses¹⁴, and VCEP-specific re-analysis conducted to refine calibrations for missense prediction.

6

The revised documentation was then used for a second phase of the pilot curation. Variants classified with inter-biocurator differences including at least one VUS and one non-VUS classification, labelled as "VUS/other", were reviewed by two additional VCEP biocurators. Variants with classification confidence differences (P versus LP, or B versus LB) were reviewed by one independent biocurator with extensive experience from the ClinGen *TP53* VCEP. Finally, code assignment was checked for all variants with concordant classification from the first pilot phase, by two VCEP biocurators. Further minor revisions were introduced following biocurator feedback on the revised documentation, and after final review from the ClinGen SVI WG.

164 Results and Discussion

An overview of the migration of the ENIGMA external expert panel to current operation as a ClinGen-approved VCEP, following FDArecognized processes, is shown in Figure 1. Development and documentation of the specifications was an iterative process that involved: (i) discussions and/or review at multiple levels (within the ClinGen SVI WG, and the VCEP members); (ii) coordination with and consideration of other ClinGen activities - including other ClinGen Hereditary Cancer Domain VCEPs, the ClinGen SVI Splicing Subgroup¹⁴, and a subgroup of the ClinGen SVI WG focussed on calibration of computational tools for missense prediction¹⁵. The extended timeline reflects the evidence-based approach taken to justify - to both VCEP and ClinGen SVI WG members - the appropriateness and/or strength of different information sources for application to *BRCA1* and *BRCA2* variants.

172

173 Overview of BRCA1 and BRCA2 Specifications

174

A broad outline of the evidence informing specifications for each baseline ACMG/AMP code is shown in Figure 2. A summary of the 175 specifications designated for each ACMG/AMP code is described in Supplemental Information. Section 2, Table S2, together with a 176 brief description of mode of application or reasons for excluding a given code. The complete ClinGen SVI WG approved specifications 177 for BRCA1 and BRCA2 VCEP are available via the ClinGen C-spec 178 registry (https://cspec.genome.network/cspec/ui/svi/affiliation/50087), together with supporting documentation, and an extensive 50 page 179 180 document with appendices describing analyses and justifications for code applicability and weighting. These specifications are expected to be updated over time to follow on scientific knowledge progress, and version changes will be documented via this same 181 portal. Summary findings reported in this study refer to Version 1.0 specifications and supporting documentation, also included here 182 as Supplemental Information, Section 3. 183

7

After initial review of ACMG/AMP criteria for relevance to interpretation of BRCA1 and BRCA2 variants, the original criterion 184 descriptions for 13 codes were considered non-applicable to these genes or overlapping (non-independent) with other criteria, largely 185 based on expert opinion (Figure 2, Table S2). Specific examples were: PS2/PM6 (de novo), given that BRCA1/2-related cancers are 186 common, and there was no information available to calibrate use of this information type: PM1 (location in a hot spot or critical 187 domain), since this was considered to be captured as a component of bioinformatic analysis, since missense prediction tools 188 inherently capture this information. In addition, directed calibration analysis was undertaken to justify that generalised use of proband 189 counting as PS4 Moderate is inappropriate for these genes due to overlap with frequency codes, and variability in evidence strengths 190 observed between cohorts.16 191

Specifications were denoted for 15 codes. Extensive data review and/or analysis from previous ENIGMA-wide and/or VCEP activities 192 193 was used to inform processes and relevant weights applicable for most of these 15 codes, as described in comprehensive supplementary documentation provided with the VCEP specifications, captured as V 1.0 in Supplemental Information, Section 3. (All 194 are made available via the ClinGen online registry for VCEP 195 versions of specifications specifications. https://cspec.genome.network/cspec/ui/svi/). Several specifications were implemented specifically to follow recommendations from 196 parallel work of the ClinGen SVI Splicing Subgroup¹⁴: codes PVS1, PS1, and BP7 were extended to capture RNA splicing 197 experimental data or in silico predictions; PS3 and BS3 were restricted to capture results from assays that measure protein functional 198 effect (either only protein impact, or protein impact that also measures underlying mRNA impact/s); and splicing impact thresholds 199 defined for SpliceAl were set for bioinformatic prediction of variant impact on splicing, captured under various codes, Probability 200 analysis combined with LR estimation¹⁷ was used to select and weight bioinformatic tool score categories for missense variant 201 prediction under PP3 and BP4. BayesDel was selected as tool of choice based on results from heterogeneity analysis, performance 202 compared to similar tools, and this tool was able to provide scores for in-frame indels. Extended calibration analysis was undertaken 203 during the pilot phase (Supplemental Information, Section 2) to include an uninformative bioinformatic score range category, and 204 205 specifically to compare BayesDel score categories to those recommended for general use by Pejaver et al.¹⁵, published during the VCEP specification process. The optimal binary cutpoint for BayesDel score prediction of impact for a missense variant within a 206 clinically important functional domain was 0.27 for BRCA1 and 0.20 for BRCA2 (Figure S1). The binary cutpoint values were used to 207 designate the central point for an uncertain zone comprised of <20% of each reference set, and for which the outer score categories 208 provided at least moderate evidence towards or against pathogenicity based on estimated LR. The VCEP opted, conservatively, to 209 apply this evidence type at supporting weight only (Table 1). Optimal BayesDel score ranges across three categories for both BRCA1 210 and BRCA2 missense prediction (Table 1) did not align with those recommended for generic use by Pejaver et al.¹⁵ (Table S3). 211

8

Specifically, use of the Pejaver et al. scale performed very poorly for benign reference set variants, in that a BP4 code (at minimum supporting strength for BayesDel \leq -0.18) would be assigned to < 10% of *BRCA1* and *BRCA2* benign reference set variants, with the large majority having no code applicable. Further, a considerable proportion (29% for *BRCA1*, 36% for *BRCA2*) would be incorrectly assigned PP3 at minimum supporting evidence strength, for BayesDel \geq 0.13.

Specification of the frequency codes PM2/BS1/BA1 was informed by a combination of LR-based methods¹⁷, and minimal credible 216 allele frequency estimation¹⁸ as recommended by ClinGen. LR estimation approaches previously used for weighting combined results 217 from functional assays¹² were repeated using an expanded dataset, and confirmed applicability of PS3 and BS3 at Strong level. 218 Extensive review of the literature and consideration of FA-designated features in GeneReviews 219 (https://www.ncbi.nlm.nih.gov/books/NBK1401/) informed the use of presence or (apparent) absence of FA phenotype for application 220 of codes PM3 and BS2, respectively. Recommendations for use and weighting of segregation data for codes PP1 and BS4 built on 221 methods previously established and enhanced for BRCA1 and BRCA2 variant interpretation by the ENIGMA consortium.^{8; 19} which 222

223 consider gene-specific age-specific cumulative risk (penetrance) and background population incidence in assessing variant causality.

The application (i.e. "criterion" description) was completely re-purposed for four codes in consultation with the ClinGen SVI WG, after 224 consideration of empirical data on BRCA1/2-related clinical features. PM5 was designated to assign exon-specific weights for a 225 premature termination codon (PTC) variant found in an exon in which functional data and/or case-control burden analysis and/or 226 family history burden analysis proves that PTCs in the exon are indeed pathogenic (as justified by VCEP analysis, Figure 3), BP1 227 was used to capture strong evidence against pathogenicity for a variant outside of a known clinically important functional domain 228 predicted to encode a silent or missense/in-frame substitution only (without known or predicted impact on splicing), with strength 229 assigned from probability based studies¹⁷, and VCEP consideration of large-scale case-control findings for missense variants.^{20; 21} 230 PP4 and BP5 were repurposed to capture combined LR estimates towards pathogenicity (PP4) or against pathogenicity (BP5), as 231 derived from calibrated multifactorial likelihood ratio analysis (but excluding any direct statistical measurement of bioinformatic 232 prediction scores, to avoid overlap with other computational codes). 233

234

235 Key considerations during development of the BRCA1 and BRCA2 specifications

236

237 Major points for discussion with key ClinGen SVI WG members before and during documentation of the draft specifications included

codes capturing bioinformatic or experimental impact on mRNA splicing; these were later resolved in part by review conducted under

- the umbrella of the ClinGen SVI Splicing Subgroup. Extensive discussion of additional codes, which at the time were new requests
 for code adaptations by a VCEP, included:
- downgrading PM2 (absence in population databases) to PM2_supporting, informed by parallel research¹⁷
- adapting the PVS1 decision tree recommendations for weighting predicted loss of function variants²² to consider
- the importance of naturally occurring rescue isoforms²³
- functional domains designated as clinically important based on location of known pathogenic missense variants (as per
 ClinGen-approved external expert panel criteria for *BRCA1* and *BRCA2* (Supplemental Information, Section 1)
- 46 duplications that preserve reading frame
- splice donor/acceptor ±1,2 dinucleotide variants for exons outside of the coding exons (5' or 3' UTRs)
- splice donor ±1,2 dinucleotide variants that create *de novo* predicted functional "GC" 5' splice sites
- repurposing PM5 to capture exon-specific evidence as additional information for classification of predicted loss of function
 stop and frameshift variants, motivated by existing clinical evidence that PTC variants are highly likely to be pathogenic
 - variants in the AG-GT splice site positions do not qualify for PM5 (PTC) code, since the mechanism of impact on mRNA transcripts may introduce variability in proportion of loss of function transcripts produced
- considering that protein domain combined with missense bioinformatic predictions, and clinical data from published case control data, achieves greater predictive value than bioinformatic missense prediction alone, and acceptance that an
 upweighted repurposed BP1_Strong code for missense and synonymous variants outside of a known (likely) clinically
 important protein domain is sufficient to achieve likely benign classification for *BRCA1* and *BRCA2* variants
- repurposing PP4 and BP5 to capture likelihood data for multiple evidence types calibrated to predict pathogenicity
- expanding potential to provide evidence against pathogenicity for data types previously only considered as positive
 predictors of pathogenicity e.g. case-control OR can be applied as PS4 only, but case-control LR estimates could be
 applied as PP4 or BP5
- increasing the breadth of information types that might be used for variant interpretation, even if not explicitly or directly
 captured by existing ACMG/AMP criteria e.g. breast tumor pathology features predictive of *BRCA1* or *BRCA2* variant
 pathogenicity are not specific to individuals with a pathogenic variant in these genes
 - allowing combined likelihoods to be captured under a single code
 - facilitating alignment with pre-existing variant classifications based on multifactorial likelihood analysis

266

264

265

251

10

There was also resolution to align code combinations to achieve variant classes following recommendations arising from Bayesian modelling of the ACMG/AMP classification system¹³, and agreement to use the points approach²⁴ to justify expansion of benign code combinations to include benign codes at moderate strength level, and use of the points approach to resolve classifications for variants with discordant benign and pathogenic code application.

271

272 Pilot application of specifications for *BRCA1* and *BRCA2* classification

273

An overview of the classifications during and after the pilot curation process is shown in Figure 4. Classifications assigned to the 40 274 pilot variants at the first and second curation phases, and the final classification assigned (with codes applied) are detailed in Table 275 S1. Pre-existing ClinVar classification for the pilot variants, based on all submitter variant assertions at the time of extraction, was as 276 277 follows: 13 VUS/conflicting, 11 P, 3 LP/P, 1 LB/B, and 12 B. After initial review, 32/40 variants achieved classification within a confidence band (LP/P or LB/B). Review of the classifications identified several reasons for the differences; new pieces of 278 unpublished internal information used by one biocurator only; unfamiliarity with data presentation; need for clarification of code use. 279 Between-curator differences often involved: recoding of published multifactorial likelihood data to ACMG/AMP codes PP4 and BP5 280 (23/40): use of frequency information (16/40): use of bioinformatic data (17/40): weighting of splicing data and use of functional data 281 (15/40). Biocurator feedback indicated the need for more specific advice for some codes, simplified tables and figures in a single 282 "specifications" document, and more detailed recommendations for interpretation of mRNA splicing data. Documentation was revised 283 accordingly, including development and inclusion of an RNA rubric for weighting of mRNA assay data. At this point, additional 284 calibration analysis was undertaken to reassess BayesDel score cut points (as per Table 1), and results incorporated into the revised 285 286 specifications.

After re-review in the second curation phase, six of eight variants assigned to "VUS/other" group in the first phase were resolved to a single classification. For variants with classifications that differed in confidence, 5/6 LP/P and all 3 LB/B resolved to a more certain classification (i.e. P or B). Compared to the original ClinVar class, classification was resolved for 11/13 VUS/conflicting variants (5 P, 1 LP, 2 VUS, 3 LB, 2 B). All variants with pre-existing ClinVar class P (11 variants) or B (12 variants) retained class. Of the remainder, 3 LP/P variants were upgraded to P, and a single LB/B variant was classified as B. As expected, variants annotated with missense or intronic molecular consequences showed greater classification uncertainty and variability (considering conflicts and confidence

11

differences) compared to premature termination codon and synonymous variants, in both initial ClinVar classification and at the first
 VCEP curation step (see Table S1 for details).

Further minor revisions of the specifications and appendices were introduced following biocurator feedback, and after final review from the ClinGen SVI WG.

297

298 Conclusions and future directions

299

Alignment of pre-existing BRCA1 and BRCA2 ENIGMA classification processes with ACMG/AMP classification criteria highlighted 300 several gaps in both the pre-existing processes and in the baseline ACMG/AMP criteria. Statistical calibration of different evidence 301 types was key to justify acceptance - or rejection - of the utility of different ACMG/AMP evidence codes for classification by VCEP 302 members, and also the ClinGen SVI WG overseeing VCEP approval. Functional evidence was lacking from the pre-existing ENIGMA 303 external panel criteria for BRCA1 and BRCA2 (Supplemental Information, Section 1), and the requirement to align with ACMG/AMP 304 processes provided motivation and mechanism for the VCEP to define suitable data sources and reach consensus on specifications 305 for this evidence type. Regarding the codes/criteria deemed not applicable, VCEP member individual opinion concerning the utility 306 of proband-counting criterion was sufficiently contentious that a separate sub study was conducted. This study demonstrated that 307 proband counting with comparison to population datasets is not sufficiently robust for generic application for BRCA1 and BRCA2. 308 given that these genes lead to relatively common diseases.¹⁶ Major items for discussions with key members of the ClinGen SVI WG 309 revolved around the need for ACMG/AMP criteria to be adapted or repurposed to capture more evidence types (and strengths), in 310 particular to provide evidence against pathogenicity. Agreement by the ClinGen SVI WG to adapt an existing code PM5 provided a 311 mechanism for additional exon-specific weighting so that pre-existing diagnostic laboratory classification practices for BRCA1 and 312 BRCA2 PTC variants would not be reversed on introduction of ACMG/AMP classification system (unless indicated by evidence in 313 this process). 314

The alignment of pre-existing ENIGMA classification methods with ACMG/AMP processes has led to benefits beyond interpretation of variants in *BRCA1* and *BRCA2*. The research-driven consideration of evidence types and calibration by the ENIGMA *BRCA1* and *BRCA2* VCEP informed the activities of the SVI Splicing Subgroup, and has already led to uptake of some of the "*BRCA1/BRCA2*" specifications for ACMG/AMP criteria by other ClinGen VCEPs. These have included: introduction of bioinformatic tiers for splicing prediction; consideration of RNA data under the PVS1 decision process; consideration of read depth for annotation of frequency

12

codes;^{25; 26} alignment of weights (for recessive disease) with *PALB2*, another gene associated with Fanconi Anemia; uptake of the
 PM5 code use for PTC variants in multiple other genes (including *ATM*, *CDH1*, *PALB2*, and *RUNX1*). It is also notable that some of
 these adaptations have been taken forward for the draft iteration of the next version of the ClinGen-promoted classification guidelines
 for application to any Mendelian gene.

The ClinGen ENIGMA BRCA1 and BRCA2 VCEP has now initiated ACMG/AMP-aligned review of BRCA1 and BRCA2 variants in 324 ClinVar. As a priority the VCEP is reviewing variants with conflicting assertions and will shortly re-assess pre-existing external expert 325 panel curations to highlight any variants expected to alter in classification after application of the VCEP specifications. VCEP review 326 of all BRCA1 and BRCA2 variants in ClinVar will be an extensive and time-consuming effort, both due to the enormity of the task 327 (11,932 BRCA1 and 17,109 BRCA2 variants as at 1st November 2023) and constraints associated with the rigorous FDA-aligned 328 ClinGen protocol, For example, after biocurator assessment of information and classification by code assignment and manual entry 329 into the ClinGen Variant Curation Interface,²⁷ three core approvers are required to review and agree with the classification. The VCEP 330 aims to introduce additional efficiencies to ease the load of biocurators in variant review, such as algorithmic code assignment based 331 on frequency and computational information in the BRCA Exchange portal (https://brcaexchange.org/)28, as a means to prioritize 332 variants for additional data collection and review. This portal will also provide a mechanism for public dissemination of VCEP-aligned 333 ACMG/AMP codes for BRCA1 and BRCA2 variants ahead of formal VCEP review. 334

In summary, this work has provided extensive evidence-based specifications to enable standardized and improved classification of variants in *BRCA1* and *BRCA2*. Further, it has more widely informed improvements in both gene-specific and generic application of the ACMG/AMP classification guidelines.

338

339 Declaration of Interests

M.A. was a paid employee of Invitae. R.C.C. and R.O. are paid employees of Color Health. M.E.R., T.P. and R.K. are paid employees of Ambry Genetics. A.R.M. and M.J.V. received funds from AstraZeneca for contribution to sponsored quality assessments and variant interpretation of BRCA1 and BRCA2 VUS (funds paid to the institution).

343 Acknowledgments

344 Refer to Supplemental Information Section 2.

13

345 Author contributions

- All authors contributed to conceptualization and writing (review and editing). Funding acquisition by F.J.C. and A.B.S. Data curation
- by M.T.P., E.T., L.C.W., M.d.I.H., and A.B.S. Formal analysis conducted by D.E.G., M.T.P, B-J.F., G.A.R.W, L.C.W., M.d.I.H., V.N.,
- M.E.R, and A.B.S. Investigation by M.T.P., W.B-F., R.C.C., M.d.I.H., S.H., M.H., H.S.L., A.R.M., R.O., M.E.R., G.S., I.S.P., B.A.T.,
- 349 M.P.G.V., L.Z., C.F. and J.H. All authors read and approved the final manuscript.

350 Web resources

351 URLs are provided in the text where appropriate.

352 Data and code availability

The published article includes all datasets generated or analyzed during this study.

Gene	BayesDel Score Category	Benign ¹	%	Pathogenic ¹	%	LR towards Pathogenicity	95% Confidence Interval	ACMG code weight applicable based on LR	ACMG bioinformatic code and weight recommended for <i>BRCA1/BRCA2</i> specifications ²	
	≤ 0.15	946	74%	34	7%	0.10	0.07-0.14	Moderate Benign	Supporting Benign (BP4)	
BRCA1	> 0.15 and < 0.28	183	14%	45	10%	0.69	0.51-0.94	No Evidence	No Evidence (not met)	
	≥ 0.28	149	12%	377	83%	7.09	6.06-8.30	Moderate Pathogenic	Supporting Pathogenic (PP3)	
	≤ 0.18	216	74%	21	16%	0.21	0.14-0.33	Moderate Benign	Supporting Benign (BP4)	
BRCA2	> 0.18 and < 0.30	46	16%	25	19%	1.18	0.73-1.90	No Evidence	No Evidence (not met)	
	≥ 0.30	29	10%	88	66%	6.59	4.40-9.90	Moderate Pathogenic	Supporting Pathogenic (PP3)	

Table 1: LR towards pathogenicity for BayesDel categories selected for BRCA1 and BRCA2 VCEP specifications

¹ Benign reference set variants were assumed benign based on no functional impact, and Pathogenic reference set variants were assumed pathogenic based on full functional impact. Based on extensive previous calibration analysis, missense prediction is considered relevant only for missense variants located within known (likely) clinically-important functional domains, and reference set variants were drawn from these regions only. See *BRCA1/2* VCEP specifications V1.0 for data sources and coding (Supplemental information, Section 3).

² Recommendation based on consensus opinion of VCEP members was to conservatively apply bioinformatic evidence at maximum Supporting weight




Figure 1: Timeline for migration from "external" expert panel to operation as a ClinGen Variant Curation Expert Panel following the ClinGen FDA-recognized protocol.

Discussions with key members of the SVI WG during 2019 relating to the strategy for alignment included the need to capture information sources used previously for *BRCA1* and *BRCA2* variant interpretation that are not explicitly designated under the baseline ACMG/AMP guidelines, especially information used in the context of multifactorial likelihood modelling. Revision of specifications at Step 3 included updates in response to ClinGen SVI Splicing subgroup recommendations¹⁴, and re-calibration of bioinformatic prediction of missense impact in response to ClinGen SVI Computational subgroup recommendations.¹⁵ Details of ENIGMA *BRCA1* and *BRCA2* Variant Curation Expert Panel membership and biocurator workforce are available at https://clinicalgenome.org/affiliation/50087/. Pre-existing ENIGMA expert panel classification guidelines for *BRCA1* and *BRCA2* are shown in Supplemental Information, Section 1, as point of reference (though no longer currently used). The final specifications approved for internal ClinGen *BRCA1*/2 VCEP use are available via https://cspec.genome.network/cspec/ui/svi/affiliation/50087.

Considerations for specification	Code	Brief description of criterion	Rationale & Criterion range of purpose	Evidence strength change
Codes/criteria deemed not	PS2, PM6	De novo	No data	N/A
applicable - largely informed by expert opinion	PS4_Moderate	Proband-counting	Non-independent of population frequency, between-cohort variability	N/A
	PM1; PM4, BP3	Hotspot; Protein length changes	Non-independent of other bioinformatic predictions	N/A
-92-	PP2, BP2	Gene/clinical/syndrome-related features	Irrelevant, based on consensus opinion	N/A
	PP5, BP6	Presence in databases	Criterion abandoned, as per ClinGen recommendation	N/A
Criterion descriptions	PVS1	Null variant	Extended – proven splicing impact captured as PVS1 (RNA)	Yes, Variable
and strengths specified after data review and	PS3, BS3	Functional data	Restricted – excludes splicing-only assay data	No
analysis	PS1	Same missense as pathogenic variant	Extended – same splicing prediction as known pathogenic variant	Yes, Variable
(previous studies, or this study)	PM2, BA1, BS1	Population frequency	Calibration informed designation of frequency bins and assigned evidence strengths	Yes
	PM3, BS2	Recessive presentation	Data review informed clinical criteria descriptions	Yes, Variable
	PP3, BP4	Bioinformatic prediction	Calibration informed designation of score categories, including a central uninformative range	No
	BP7	Silent variant	Extended - intronic variants	No
			Extended - splicing data captured as BP7 (RNA)	Yes, Strong
	PS4	Case-Control odds ratio	Note: Preferentially apply as case-control LR (PP4, BP5)	No
	PP1, BS4	Co-segregation	Extended – captures age-specific penetrance models	Variable
Codes repurposed to align with existing	PM5	Missense change at residue with another pathogenic missense >> Protein termination codon (PTC) variant in an exon with a different proven PTC	Burden analysis provides exon-specific evidence for pathogenicity of PTC variant/s	Variable
evidence-based protocols.	PP4, BP5	Phenotype specific for disease, Variant found in case with alternative molecular basis >> Combined likelihood ratio data from calibrated analyses	Any calibrated information predictive of variant pathogenicity can be utilized	Variable
	BP1	Missense variant in gene with primarily truncating pathogenic variants >> Missense/silent variant, with no predicted splicing, located outside a functional domain	Calibration analysis indicates that variant location outside of a known protein functional domain is a strong predictor against pathogenicity	Yes, Strong

Figure 2: Outline of BRCA1 and BRCA2 VCEP specifications designated for baseline ACMG/AMP codes and criteria.

Code designations, and original criterion descriptions for codes, are derived from Richards et al 2015.⁹ For repurposed codes, the original criterion description is noted in light blue font, and a broad description is provided for the evidence type to be captured as per specifications. Evidence strength changes are recorded as follows: N/A – not applicable; No - codes used only at original specified weight; Yes - codes used with changed weight; Variable – different strength options can be applicable. Evidence strengths were informed by Bayesian modelling results.^{13; 24} Splicing-related codes were informed by parallel work.¹⁴




Figure 3: Overview of evidence supporting PM5 exon-specific weights application for premature termination codon variants in BRCA1 (A) and BRCA2 (B)

Exon-specific points assigned are derived from per-exon evidence, as follows: observed experimental impact on function for at least one premature termination codon (PTC) variant in an exon, to infer code PS3 for another PTC variant in the same exon (Fxn PTC, assigned 4 points); observed experimental impact on function for at least one missense substitution variant in the exon indicates no rescue of pathogenic variants due to alternative splicing, and that a PTC variant leading to nonsense mediated decay would have at minimum the same impact - used to infer code PS3 moderate for another PTC variant in the same exon (Fxn Missense, assigned 2 points); Case-control Odds Ratio $(OR) \ge 4.0$ estimated for PTC variants observed in a given exon, to infer code PS4 for any PTC variant in that exon (CaCo OR \geq 4), assigned at full strength for a statistically significant association (4 points), and at supporting strength for non-significant estimates (1 point); family history likelihood ratio (LR) estimates from heterogeneity analysis, using personal and family history profile as a predictor of pathogenicity in a clinical dataset²⁹ (Fam History LR, assigned points based on LR); standardized incidence ratio (SIR) ≥4.0, for PTC variants in non-Finnish European (NFE)

6

probands with breast, ovarian and/or pancreatic cancer in a clinical dataset sourced from Ambry Genetics²⁹ versus the summed frequency of PTC in gnomAD NFE (Ambry SIR/OR), with SIR ≥ 4, P<0.05 was used to infer code PS4 (4 points), and SIR \geq 4 non-significant as PS4_supporting (1 point); identification of PTC variants in a given exon in multiple independent probands in the CIMBA (https://cimba.ccge.medschl.cam.ac.uk/) highly ascertained cohort of BRCA1 and BRCA2 pathogenic variant carriers (including patients who historically met strict clinical criteria to undergo diagnostic testing), with observation of ≥5 unique PTCs variant in ≥ 5 CIMBA families used to infer PP4 (CIMBA, 1 point). The per-exon evidence was summed across the different evidence types (Fxn PTC, Fxn Missense, CaCo OR ≥4, Fam History LR, Ambry SIR/OR, CIMBA), to derive an exon-specific evidence strength using a points-based approach (Supporting = 1 point, Moderate = 2 points, Strong = 4 points). Based on the combined evidence, the PM5 (PTC) code can be applied as Strong evidence in favour of pathogenicity for most exons. The PM5 (PTC) code can only be applied to germline variants that meet PVS1 codes, namely nonsense and frameshift changes, including large deletions and tandem duplications. Code weight is determined by the exon in which the predicted termination codon occurs. For example, a frameshift variant in BRCA2 exon 15 that is predicted to result in a PTC within exon 16 would use the code strength of BRCA2 exon 16 (PM5_Strong (PTC)). Variants in the AG-GT splice site positions do not qualify for PM5 (PTC) code.




Figure 4: Overview of variant classifications assigned during pilot of VCEP specifications.

Sankey diagram shows transition in classification categories for pilot variants, from initial ClinVar classification to final classification assigned by the VCEP. The left column represents the initial ClinVar classification category/grouping of pilot variants. The central column represents classification/s by biocurators after the initial pilot phase. The right column represents the final classifications of pilot variants. Classification categories: P=Pathogenic; LP=Likely Pathogenic; VUS=Variant of uncertain significance; Conflict=conflicting; LB=Likely Benign; B=Benign. For each category/grouping, the number of variants is shown in parentheses. Final VCEP curation resulted in increased certainty in classification for all variants with initial LP/P or B/LB category, movement of three of four variants with initial VUS classification outside of this category, and resolution in classification for the nine variants with initial conflicting classification - eight reaching classification other than VUS.

References

- 1. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.
- 2. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.
- 3. Spurdle, A.B., Healey, S., Devereau, A., Hogervorst, F.B., Monteiro, A.N., Nathanson, K.L., Radice, P., Stoppa-Lyonnet, D., Tavtigian, S., Wappenschmidt, B., et al. (2012). ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 33, 2-7.
- 4. Caputo, S.M., Golmard, L., Leone, M., Damiola, F., Guillaud-Bataille, M., Revillion, F., Rouleau, E., Derive, N., Buisson, A., Basset, N., et al. (2021). Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. Am J Hum Genet 108, 1907-1923.
- 5. Goldgar, D.E., Easton, D.F., Byrnes, G.B., Spurdle, A.B., Iversen, E.S., Greenblatt, M.S., and Group, I.U.G.V.W. (2008). Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29, 1265-1272.
- 6. Goldgar, D.E., Easton, D.F., Deffenbaugh, A.M., Monteiro, A.N., Tavtigian, S.V., Couch, F.J., and Breast Cancer Information Core Steering, C. (2004). Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75, 535-544.
- 7. Lindor, N.M., Guidugli, L., Wang, X., Vallee, M.P., Monteiro, A.N., Tavtigian, S., Goldgar, D.E., and Couch, F.J. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33, 8-21.
- 8. Thompson, D., Easton, D.F., and Goldgar, D.E. (2003). A full-likelihood method for the evaluation of causality of sequence variants from family data. Am J Hum Genet 73, 652-655.
- 9. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17, 405-424.
- 10. Rehm, H.L., Berg, J.S., Brooks, L.D., Bustamante, C.D., Evans, J.P., Landrum, M.J., Ledbetter, D.H., Maglott, D.R., Martin, C.L., Nussbaum, R.L., et al. (2015). ClinGen--the Clinical Genome Resource. N Engl J Med 372, 2235-2242.
- 11. Rivera-Munoz, E.A., Milko, L.V., Harrison, S.M., Azzariti, D.R., Kurtz, C.L., Lee, K., Mester, J.L., Weaver, M.A., Currey, E., Craigen, W., et al. (2018). ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. Hum Mutat 39, 1614-1622.
- 12. Parsons, M.T., Tudini, E., Li, H., Hahnen, E., Wappenschmidt, B., Feliubadalo, L., Aalfs, C.M., Agata, S., Aittomaki, K., Alducci, E., et al. (2019). Large scale multifactorial likelihood guantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum Mutat 40, 1557-1578.
- 13. Tavtigian, S.V., Greenblatt, M.S., Harrison, S.M., Nussbaum, R.L., Prabhu, S.A., Boucher, K.M., Biesecker, L.G., and ClinGen Sequence Variant Interpretation Working, G. (2018). Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20, 1054-1060.
- 14. Walker, L.C., Hoya, M., Wiggins, G.A.R., Lindy, A., Vincent, L.M., Parsons, M.T., Canson, D.M., Bis-Brewer, D., Cass, A., Tchourbanov, A., et al. (2023). Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. Am J Hum Genet 110, 1046-1067.
- 15. Pejaver, V., Byrne, A.B., Feng, B.J., Pagel, K.A., Mooney, S.D., Karchin, R., O'Donnell-Luria, A., Harrison, S.M., Tavtigian, S.V., Greenblatt, M.S., et al. (2022). Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am J Hum Genet 109, 2163-2177.
- 16. Cristina Fortuno, K.M., Michael Parsons, Jill S. Dolinsky, Tina Pesaran, Amal Yussuf, Jessica L. Mester, Kathleen S. Hruska, Susan Hiraki, Robert O'Connor, Raymond C. Chan, Serra Kim, Sean V. Tavtigian, David Goldgar, Paul

A. James, Amanda B. Spurdle. Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines. Hum Mol Genet In Press.

- 17. Thomassen, M., Mesman, R.L.S., Hansen, T.V.O., Menendez, M., Rossing, M., Esteban-Sanchez, A., Tudini, E., Torngren, T., Parsons, M.T., Pedersen, I.S., et al. (2022). Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach. Hum Mutat 43, 1921-1944.
- 18. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y., Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., et al. (2017). Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med 19, 1151-1158.
- 19. Belman, S., Parsons, M.T., Spurdle, A.B., Goldgar, D.E., and Feng, B.J. (2020). Considerations in assessing germline variant pathogenicity using cosegregation analysis. Genet Med 22, 2052-2059.
- 20. Breast Cancer Association, C., Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Luccarini, C., Wahlstrom, C., Pooley, K.A., Parsons, M.T., Fortuno, C., et al. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med 384, 428-439.
- 21. James, P.A., Fortuno, C., Li, N., Lim, B.W.X., Campbell, I.G., and Spurdle, A.B. (2022). Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. Hum Mutat 43, 882-888.
- 22. Abou Tayoun, A.N., Pesaran, T., DiStefano, M.T., Oza, A., Rehm, H.L., Biesecker, L.G., Harrison, S.M., and ClinGen Sequence Variant Interpretation Working, G. (2018). Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat 39, 1517-1524.
- 23. de la Hoya, M., Soukarieh, O., Lopez-Perolio, I., Vega, A., Walker, L.C., van Ierland, Y., Baralle, D., Santamarina, M., Lattimore, V., Wijnen, J., et al. (2016). Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet 25, 2256-2268.
- 24. Tavtigian, S.V., Harrison, S.M., Boucher, K.M., and Biesecker, L.G. (2020). Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat 41, 1734-1737.
- 25. Davidson, A.L., Leonard, C., Koufariotis, L.T., Parsons, M.T., Hollway, G.E., Pearson, J.V., Newell, F., Waddell, N., and Spurdle, A.B. (2021). Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. Hum Mutat 42, 530-536.
- 26. Luo, X., Maciaszek, J.L., Thompson, B.A., Leong, H.S., Dixon, K., Sousa, S., Anderson, M., Roberts, M.E., Lee, K., Spurdle, A.B., et al. (2023). Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines. J Med Genet 60, 568-575.
- 27. Preston, C.G., Wright, M.W., Madhavrao, R., Harrison, S.M., Goldstein, J.L., Luo, X., Wand, H., Wulf, B., Cheung, G., Mandell, M.E., et al. (2022). ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines. Genome Med 14, 6.
- 28. Cline, M.S., Liao, R.G., Parsons, M.T., Paten, B., Alquaddoomi, F., Antoniou, A., Baxter, S., Brody, L., Cook-Deegan, R., Coffin, A., et al. (2018). BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet 14, e1007752.
- 29. Li, H., LaDuca, H., Pesaran, T., Chao, E.C., Dolinsky, J.S., Parsons, M., Spurdle, A.B., Polley, E.C., Shimelis, H., Hart, S.N., et al. (2020). Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. Genet Med 22, 701-708.